Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion [Seeking Alpha]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Seeking Alpha
China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, from San Francisco's Incyte for autoimmune and inflammatory dermatologic diseases. Suzhou's Innovent Biologics and HutchMed of Shanghai filed an NDA in China for a combination therapy aimed at advanced endometrial cancer. Deals and Financings ProfoundBio, a Seattle ADC company with an R&D facility in Suzhou, will be acquired by Copenhagen's Genmab A/S ( GMAB ) in a $1.8 billion all-cash deal (see story ). The acquisition will expand Genmab's drug portfolio, including three ProfoundBio clinical-stage ADC candidates for solid tumors. The company's three clinical-stage assets target ovarian cancer and other FRa-expressing solid tumors. A privately owned company, ProfoundBio raised $112 million in a B Round financing earlier this year. ProfoundBio is led by CEO Baiteng Zhao, a former associate director at Seagen, a Seattle ADC company that was acquired by Pfizer for $43 billion in 2023. Shanghai's Visen Pharma
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer [Yahoo! Finance]Yahoo! Finance
- TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerBusiness Wire
- TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerGlobeNewswire
- Unveiling AbbVie's Winning Strategy In Pharmaceutical Innovation (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Cancer-Drug Maker Janux Therapeutics Weighs Possible Sale [BNN Bloomberg (Canada)]BNN Bloomberg